Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416223 | 1.00 | IDO1 (0.51) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL21259457 | 0.87 | IDO1 (0.46) | IDO1NOS1AXLMETAP2GLS | |
| SCHEMBL2633084 | 0.85 | IDO1 (0.55) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL4686743 | 0.84 | JAK2 (0.44) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL13554518 | 0.82 | NOS1 (0.50) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL27663105 | 0.82 | NOS1 (0.50) | IDO1NOS1AXLMETAP2JAK2 | |
| Bromide SCHEMBL27530305 | 0.81 | NOS1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL12272344 | 0.79 | NOS1 (0.47) | IDO1NOS1AXLMETAP2JAK2 | |
| Hydrochloric Acid SCHEMBL12491055 | 0.78 | NOS1 (0.46) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL12272435 | 0.78 | NOS1 (0.46) | IDO1NOS1AXLMETAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023020519-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192891-B2 | Diazaspiro ROCK inhibitors | ROCK1, MYLK, ROCK2 | IDO1 431/4885NOS1 31/4885AXL 1039/4885 |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | ROCK1, MYLK, ROCK2 | IDO1 431/4885NOS1 31/4885AXL 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.